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ABSTRACT
Angiosarcoma is an aggressive malignancy of vascular origin that occurs de
novo or in the context of previous cancer therapy. Despite multi-modal aggressive
treatment including surgical resection, chemotherapy, and radiation, five-year overall
survival remains poor at 35%. Due to its rarity, little is known about its molecular
pathology and clinical trials have been extremely difficult to conduct. Development
of animal models for rare diseases like angiosarcoma is critical to improve our
understanding of tumorigenesis and to test novel treatment regimens. A genetically
engineered mouse model for angiosarcoma was generated by conditional deletion
of Trp53, Pten, and Ptpn12 in endothelial cells. Tumors arising from these mice
recapitulate the histology and molecular pathology of the human disease including
hyperactivation of the PI3K/mTOR and MAPK signaling pathways. Treatment of
tumor-bearing mice with mTOR or MEK inhibitors effectively inactivated signaling and
resulted in reduced proliferation and elevated apoptosis leading to tumor regression.
The effect of treatment on tumor growth was transient and proliferation was restored
after a period of dormancy. However, combined inhibition of mTOR and MEK resulted
in profound tumor regression which was sustained for the duration of treatment.
These results suggest that angiosarcoma may be effectively treated by this drug
combination.

INTRODUCTION

and a lack of available model systems, relatively little is
known about the molecular pathogenesis of angiosarcoma. In
order to develop novel targeted therapeutic regimens for this
disease, a greater understanding of the signaling pathways
driving tumor growth and models with which to interrogate
these pathways are needed.
Although only a few reports have described the
driver mutations leading to angiosarcoma development,
these reveal the presence of recurrent pathway
aberrations. Specifically, mutations leading to activation

Angiosarcoma is a rare malignancy of the vascular
endothelium accounting for approximately 2% of all soft
tissue sarcomas. The approach to treatment is multimodal and
includes complete surgical resection where possible followed
by chemotherapy and radiation therapy in cases of metastatic
disease [1, 2]. Despite aggressive therapy, 5-year overall
survival varies from 31% to 43% and is significantly worse
with metastatic disease [3–7]. Due to the rarity of the disease
www.oncotarget.com
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of the phosphatidylinositol-3ʹ-kinase/mammalian target
of rapamycin (PI3K/mTOR) and RAS/mitogen-activated
protein kinase (MAPK) pathways have been reported.
One study found activating mutations in PIK3CA in
40% of tumors [8] while other investigators describe
elevated levels of phosphorylated S6 in 100% [9] and
phosphorylated 4EBP1 in 88% of angiosarcomas [10],
both of which are downstream effectors of mTOR.
Importantly, one study demonstrated that treatment
with the mTOR inhibitor rapamycin decreases cell
proliferation in vitro and delayed tumor growth in vivo
using a xenograft model [9]. Interestingly, a trial of the
mTOR inhibitor everolimus in patients with recurrent soft
tissue sarcomas reported that the progression free rate was
highest in angiosarcoma patients compared to patients
with other high-grade sarcomas [11]. Seki et al. observed
a partial response of an angiosarcoma patient treated with
ridaforolimus, another mTOR inhibitor [12]. Mutations
in KRAS have been found in 13–60% of angiosarcomas
as well, leading to activation of both the PI3K/mTOR
and MAPK pathways [13–16]. A recent deep sequencing
study investigated mutations in the RAS/MAPK pathway
comprehensively and found that 53% of angiosarcomas
contained hotspot mutations in KRAS, HRAS, NRAS,
BRAF, or MAPK1 [17]. To our knowledge, there are no
clinical trials of BRAF or MEK inhibitors in patients with
angiosarcoma, although one case report described a child
with angiosarcoma bearing a KRAS mutation who did
not respond to the MEK inhibitor trametinib [18]. TP53
mutations have been noted in 35% to 52% of samples
in various studies [16, 17, 19–22]. Moreover, evidence
for the involvement of p53 comes from Li-Fraumeni
patients who are at increased risk for angiosarcoma [23].
Recently, a genome sequencing effort discovered recurrent
mutations in PTPRB, a vascular endothelial cell-specific
protein tyrosine phosphatase (PTP) that regulates receptor
tyrosine kinases (RTKs), in angiosarcoma [16].
PTPN12 is a PTP that has been shown to
dephosphorylate RTKs as well as proteins involved in cell
migration [24–27]. Developmentally, Ptpn12 expression is
critical as knockout mice die around E10.5 due in part to
impaired embryonic vascularization [28]. Several studies
have proposed a tumor suppressive role for PTPN12 in
various cancers including breast, prostate, colon, kidney,
melanoma, and esophageal carcinoma [29–33]. In breast
cancer, PTPN12 loss resulted in a block in apoptosis and
increased migration and invasion [34]. Furthermore, in
triple negative breast cancer, loss of PTPN12 has been
shown to substitute for amplification of RTKs, and
leads to downstream activation of the MAPK pathway.
PTPN12-null breast cancer cells were also found to have
enhanced metastatic potential [24]. Similarly, decreased
expression of PTPN12 in colon cancer cell lines resulted
in increased cellular migration [31]. Collectively, these
data suggest that PTPN12 plays an important role in
disease progression in a variety of cancers.
www.oncotarget.com

We have developed a novel mouse model for
angiosarcoma that encompasses deletion of Pten, Trp53,
and Ptpn12 in vascular endothelial cells. Deletion of these
three genes in concert results in angiosarcoma with complete
penetrance and short latency. We demonstrate co-activation
of the PI3K/mTOR and MAPK pathways in murine and
human tumors and show that in vivo concurrent inhibition of
mTOR and MEK results in sustained tumor regression.

RESULTS
Loss of Pten, Trp53, and Ptpn12 results in
angiosarcoma
We engineered mice that inducibly delete Pten,
Trp53, and Ptpn12 using a GFAP-CreER mouse driver
line. Tamoxifen is administered for three consecutive days
between P28 and P44, a time frame chosen to circumvent
developmental defects (Figure 1A). We analyzed cohorts
of mice with all combinations of single, double and triple
gene deletions and found that mice in three of the cohorts
[double knockout (DKO) for Trp53 and Ptpn12, DKO for
Pten and Ptpn12, and triple knockout (TKO) for Trp53,
Pten and Ptpn12] developed multiple dark cutaneous
lesions (Figure 1B), which were easily detectable on
the FVB albino background (Figure 1C). Histologic
evaluation of the lesions revealed aggressive vascular
lesions with anastomosing and solid areas composed
of vascular channels lined by pleomorphic endothelial
cells, and numerous typical and atypical mitotic figures
(Figure 1D). The tumor cells stained strongly for CD31
(a vascular endothelial marker) and were negative for
PROX1 (a lymphendothelial marker) consistent with a
malignant vascular neoplasm. The resemblance of the
histology of the mouse lesion to human angiosarcoma was
striking (Figure 1D). Intriguingly, we noted that the three
cohorts of mice that developed angiosarcoma all include
the deletion of Ptpn12 (Figure 1B). DKO mice for Pten
and Trp53 develop other subcutaneous tumors in addition
to high grade glioma, but none develop cutaneous vascular
lesions (data not shown). This suggests a critical role for
the Ptpn12 gene in tumor suppression with specificity for
angiosarcoma. TKO mice develop tumors with higher
penetrance and shorter latency than either of the two
DKO genotypes with nearly 100% of mice developing
angiosarcomas (Figure 1B). PCR amplification of tumor
DNA confirmed Cre-mediated recombination of Pten,
Trp53, and Ptpn12 (Supplementary Figure 1A).
In order to determine why the GFAP-CreER mouse
line is driving tumors of endothelial origin, we performed
co-immunofluorescence (IF) using antibodies directed
against β-galactosidase (which was included as a marker
gene on the bicistronic CreER transgene) and CD31. We
found that a small percentage of endothelial cells also
express β-gal, indicating that CreER is expressed in these
cells (Supplementary Figure 1B). Moreover, we crossed
24751
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the GFAP-CreER mouse line with Rosa-tdTomato reporter
mice and demonstrated Cre-mediated recombination in
CD31-positive cells of the skin (Supplementary Figure 1C).
Lastly we used an endothelial cell-specific Cre driver,
Tie2-CreER and found that the TKO combination also
developed angiosarcomas, albeit with a broader tissue
distribution when compared to the GFAP-CreER mice
(Supplementary Figure 1D). Tumors in the GFAP-CreER
mice are generally cutaneous and occur most frequently on
the head, extremities, and perianally. Visceral tumors were
found in the mediastinum although this occurred in a small
percentage of mice (Figure 1C). When tumors from all three
genetic combinations were compared, all were found to
have a similar immunophenotype with respect to CD31 and

PROX1 expression and all demonstrated a high proliferative
index as indicated by KI67 staining (Figure 1D). The
TKO and Trp53; Ptpn12 DKO tumors were classified as
high-grade angiosarcoma due to the prominent nuclear
pleomorphism, atypical mitosis and solid tumor areas
observed while tumors from the Pten; Ptpn12 DKO mice
were classified as low-grade with minimal atypia, lack of
atypical mitosis and anastomosing morphology.

Activation of the PI3K/mTOR and MAPK
pathways in murine angiosarcoma
In order to investigate pathways involved in the
pathogenesis of murine angiosarcoma we first characterized

Figure 1: Ptpn12 deletion leads to angiosarcoma in mice. (A) Schematic for development of triple knockout angiosarcoma mouse

model. (B) Kaplan–Meier curve demonstrating incidence of angiosarcoma in the seven mouse lines generated. Ptpn12 KO n = 42, Trp53
KO n = 9, Pten KO n = 8, Pten;Ptpn12 KO n = 10, Trp53;Ptpn12 KO n = 13, Trp53;Pten KO n = 10, triple KO n = 30. (C) Pathology
and histology of murine angiosarcomas. Gross dissection of the mouse is shown in the upper panels. Red arrows point to angiosarcomas.
Images of the hematoxylin and eosin stained tumors is shown in the lower panels and letter-matched to the gross pictures above (a–h). Scale
bar in (h) is 50 µm and applies to all images in the lower panel. (D) Histology of human angiosarcoma found in bone compared to the three
genotypes of mice that develop angiosarcomas. Scale bar in the top right panel is 100 µm and applies to the first row, scale bar in the panel
below is 50 µm and applies to all remaining pictures.
www.oncotarget.com
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The mTOR and MAPK pathways can be
effectively inhibited using targeted therapies

the expression of known endothelial cell markers in the
tumors. CD31 and VEGFR1 are expressed in angiosarcomas
at levels comparable to that of CD31+ endothelial cells
isolated from mouse lung, while VEGFR2, VEGFR3, and
VE-cadherin were relatively overexpressed when compared
to the control lung endothelial cells (Figure 2A). These
results underscore the vascular nature of these tumors. We
then focused on the analysis of the PI3K/mTOR and MAPK
pathways as these are known to be regulated respectively
by two of the targeted genes, Pten and Ptpn12. Western
blot analysis revealed that phospho-4EBP1 is elevated
in all tumors including those that were Pten wild-type,
suggesting that activation of the mTOR pathway is important
for angiosarcoma growth (Figure 2B). Phospho-MAPK
is also elevated across all genotypes as expected since
loss of Ptpn12 was common to all tumors. In agreement,
we also demonstrated, by immunohistochemistry, high
levels of phospho-S6 and phospho-MAPK in tumors of all
genotypes (Figure 2C). As expected, PTEN was absent in the
Pten;Ptpn12 DKO and TKO tumors; however, surprisingly,
very low levels were also detected in the Trp53;Ptpn12 DKO
tumors (Figure 2A and 2C). STAT3 phosphorylation was
evaluated to determine if there was generalized activation of
all downstream RTK pathways. However, phospho-STAT3
was not consistently elevated in angiosarcomas relative to
endothelial cell controls (data not shown).
We were particularly interested in identifying target(s)
of PTPN12 activity critical for angiosarcomagenesis.
We first took a candidate approach to test whether RTKs
involved in endothelial cell signaling and PTPN12
effectors are phosphorylated in angiosarcomas. Tyrosine
phosphorylated proteins were immunoprecipitated
from TKO angiosarcoma tumor lysates and blotted for
the VEGF receptors (Supplementary Figure 2A–2G).
Receptor phosphorylation was either not detected in
anti-phosphotyrosine immunoprecipitates (VEGFR1,
Supplementary Figure 2A), detected at similar levels
compared to control lung tissue (VEGFR2, Supplementary
Figure 2B, 2D) or tyrosine phosphorylation was not
detected in the reciprocal receptor immunoprecipitation
experiment (VEGFR3, Supplementary Figure 2C, 2E).
Therefore we decided to use an RTK antibody array to
screen for hyperphosphorylated receptor tyrosine kinases
in murine angiosarcoma. We found that PDGFR-β was
phosphorylated in all three angiosarcoma models and was
particularly prominent in Ptpn12; Pten DKO tumors in
which this was the only RTK with elevated phosphorylation
in the array (Supplementary Figure 2H). This finding was
verified by anti-phosphotyrosine immunoprecipitation of
lysates from TKO tumors followed by western blotting for
PDGFR-β as well as by the reciprocal immunoprecipitation
experiment (Figure 2D). Furthermore, the presence of high
levels of PDGFR-β expression was confirmed by IHC in
all three models (Figure 2E). These findings are interesting
as PDGFR-β has previously been shown to be a target of
PTPN12 [24, 25, 35].
www.oncotarget.com

In order to determine whether these pathways are
important for the growth of murine angiosarcomas we
treated our most aggressive model, the TKO mice, with
small-molecule targeted inhibitors. We used rapamycin,
an inhibitor of mTOR and trametinib, an inhibitor of
MEK1 and 2, both of which are FDA-approved drugs.
To determine the lowest biochemically effective dose of
each drug, we treated mice whose tumor measured at least
5mm in its longest diameter daily for five days. Five doses
of rapamycin were tested in vivo: 25 mg/kg, 10 mg/kg,
5 mg/kg, 3 mg/kg, and 1 mg/kg. Rapamycin effectively
inhibited the mTOR pathway down to a dose of 3 mg/kg
as assessed by phosphorylation of AKT, S6, and 4EBP1
by Western blot and IHC (Supplementary Figure 3A–3F).
Phosphorylation of AKT at S473 is mediated by
mTORC2, not mTORC1; however, in some cell lines
such as endothelial cells, prolonged exposure to rapamycin
can suppress phospho-AKT [36, 37]. At the lowest dose
tested, 1 mg/kg, phosphorylation of AKT and 4EBP1 was
not significantly diminished; however, S6 phosphorylation
remained low (Supplementary Figure 3E). A significant
biological effect of treatment with rapamycin was
also noted as tumor cell proliferation was decreased
and apoptosis, as measured by cleaved caspase-3 was
increased (Supplementary Figure 3E, 3F). Moreover all
treatment doses tested resulted in regression of tumor size
over the five day period of observations (Supplementary
Figure 3G). Importantly, treatment with rapamycin
appeared to result in an increase in phosphorylation of
MAPK suggesting that the tumor cells were attempting
to compensate for the loss of proliferative signals from
mTORC1 inhibition (Supplementary Figure 3A, 3D, 3E).
The MEK inhibitor, trametinib was tested at three
different doses in vivo: 3 mg/kg, 2 mg/kg, and 1 mg/kg.
We found that phosphorylation of MAPK is effectively
inhibited at a dose of 2 mg/kg or greater while partial
inhibition was seen at 1 mg/kg by Western blot and IHC
(Supplementary Figure 4A–4D). All treatment doses
significantly decreased proliferation as measured by KI67
and increased apoptosis as detected by cleaved caspase-3
(Supplementary Figure 4C–4D). As was observed with
rapamycin treatment, trametinib treatment at all doses was
able to shrink established tumors over the course of five
days (Supplementary Figure 4E). Interestingly, the effect
on mTOR pathway signaling with MEK inhibition varied
at each node. AKT phosphorylation was slightly increased
while S6 phosphorylation was diminished and that of
4EBP1 remained relatively unaffected (Supplementary
Figure 4A, 4C).
We tested combined treatment of both rapamycin and
trametinib in vivo compared to either drug alone at a dose
of 1 mg/kg for 5 days so that we could detect if synergistic
or additive effects were present. Dual treatment with these
24753
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inhibitors resulted in a more profound suppression of
signaling in the PI3K/mTOR and MAPK pathways than
was seen with either treatment alone at the same dose
(Figure 3A). In particular, phospho-4EBP1 was reduced by
the dual treatment compared to treatment with rapamycin
alone and phospho-MAPK was also diminished compared
to treatment with trametinib alone (Supplementary
Figure 5A and 5C). Importantly the compensatory
hyperphosphorylation of MAPK induced by treatment with
rapamycin alone was completely reversed by the addition
of trametinib (Supplementary Figure 5C). Similarly
increased phosphorylation of both MEK and AKT induced
by trametinib was reversed by the addition of rapamycin
(Figure 3A and Supplementary Figure 5B). Despite the
enhanced biochemical effect on the pathways induced by

dual inhibitor treatment, proliferation was similar when
compared to either treatment alone (Figure 3B and 3C)
and cell death as measured by TUNEL staining was also
similar to rapamycin treatment alone (Figure 3B and 3D).
Again, there was a significant regression of tumors over the
five day treatment period when compared to vehicle treated
animals, but this effect was similar to that of either drug
treatment alone (Figure 3E).

Long-term treatment with mTOR and MEK
inhibitors is synergistic and results in a sustained
anti-tumor response
In view of the robust biochemical response to
rapamycin and trametinib and evidence for tumor

Figure 2: mTOR and MAPK pathways are activated in murine angiosarcoma. (A) Western blots analyzing different

endothelial cell markers in protein lysates prepared from HUVECs untreated (–) or treated (+) with VEGFA, total lung, endothelial cells
isolated from lung using CD31 beads, tumors from both Trp53; Ptpn12 and Pten; Ptpn12 DKO mice, and tumors from TKO mice. (B)
Western blots using the same protein lysates as in (A) but investigating the indicated signaling molecules. (C) Immunohistochemical
staining on tissue sections from a representative tumor from each of the indicated mouse genotypes. Scale bar in the top right panel is
50 µm and applies to all pictures. (D) Anti-phosphotyrosine immunoprecipitations (IP) from control lung and TKO angiosarcoma protein
lysates were then probed for PDGFR-β (left panel). The reciprocal immunoprecipitation and blotting experiment (middle panel) and total
PDGFR-β comparisons (right panel) are shown. The input lane represents 20 µg of protein lysate from the tumor while IPs were performed
from 500 µg protein lysate. (E) Tumors from the indicated mouse genotypes were stained by IHC for PDGFR-β. Scale bars are 50 µm.
www.oncotarget.com
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regression after only five days of treatment, which was
well tolerated by animals, a long-term treatment and
survival study was carried out. TKO mice were observed
until a single angiosarcoma reached a calculated volume
of 100 mm3. They were then assigned to one of four
treatment arms: vehicle, rapamycin, trametinib, or dual
therapy using rapamycin and trametinib at 1 mg/kg each.
All treatments were administered daily (seven days a
week) continuously until the animal developed morbidity
from tumor growth or from the treatment, or until they
reached 140 days of treatment whichever came first.
As was observed during five-day treatments of mice,
all drug treatments were equally effective at inducing
tumor regression when compared to the vehicle control
(Figure 4A). However, most of the tumors treated with

Rapamycin and every tumor treated with Trametinib
regrew aggressively between 40 to 80 days of treatment
(Figure 4B). In contrast mice treated with both inhibitors
experienced tumor regression which was sustained over
the 140 day treatment period (Figure 4A). None of the
dual drug treated mice succumbed to tumor growth
while receiving treatment (Figure 4B), however several
animals did die of presumed toxicity of the combined
inhibitors (dehydration leading to a moribund state). As
a consequence, overall survival of dual inhibitor treated
mice was not improved compared to either inhibitor alone
(Supplementary Figure 6A). Full necropsy of these animals
did not reveal the presence of metastatic disease or any
other tumor growth. Importantly, angiosarcomas recurred
in mice upon withdrawal of the drugs after 140 days

Figure 3: Five-day treatment with trametinib, rapamycin, or a combination of both results in disease regression.
(A) Western blots of signaling molecules on protein lysates prepared from tumors isolated from treated TKO mice comparing vehicle,
rapamycin, trametinib or both drugs all administered at a dose of 1 mg/kg. (B) IHC demonstrating proliferation (KI67), apoptosis (cleaved
caspase-3 and TUNEL), mTOR (pS6), and MAPK (pMAPK) pathway signaling in tumors from the same groups of mice as above.
Scale bar in the top right panel is 50 µm and applies to all panels. (C) Quantification of KI67 staining from (B). *P ≤ 0.05 applies to all
comparisons indicated. (D) Quantification of TUNEL staining from (B). (E) Comparison of the fold change in tumor volume over the
course of the five day treatments. **P ≤ 0.01 applies to all treatment groups compared to vehicle.
www.oncotarget.com
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Activation of the PI3K/mTOR and MAPK
pathways in human tumors of vascular origin

of treatment indicating the persistence of viable tumor
cells (Figure 4A).
Response to inhibitor treatment was also assessed by
waterfall plot (Figure 4C). This analysis demonstrated that
the best responses were achieved in mice who received
both rapamycin and trametinib concurrently. Remarkably,
14 of the 15 tumors treated with both inhibitors achieved
a partial response (defined as a decrease in tumor volume
by at least 50%). This rate of response was significantly
greater than that seen in vehicle or trametinib treated mice,
and approached statistical significance when compared to
rapamycin treatment (Table 1).
To determine the cause of tumor recurrence after
prolonged treatment with either inhibitor alone, tumors
were assessed for pathway activation at various time points
indicated in Figure 4A (a–e). Tumors that recurred while
on rapamycin treatment maintained complete repression
of phospho-S6; similarly, tumors that recurred while on
treatment with trametinib exhibited low levels of phosphoMAPK (Figure 4D, Supplementary Figure 6B, 6C). These
results suggest that tumor recurrence is not due to loss of
the ability of rapamycin or trametinib to suppress their
molecular targets, but rather to the development of parallel
pathways that support renewed tumor growth. In fact,
IHC for KI67 on recurrent tumors revealed brisk levels
of proliferation similar to levels seen in vehicle treated
tumors while proliferation remained low in dual inhibitor
treated tumors. Elevated apoptosis persisted in treated
tumors as detected by TUNEL staining (Figure 4D–4F). In
tumors treated for five days with rapamycin or trametinib,
hyperactivation of the uninhibited pathway was noted
(Figure 3A, 3B and Supplementary Figure 5B, 5C). In the
long-term treatments, some tumors continued to exhibit
similar hyperphosphorylation however this was not
consistently seen in all tumors. Therefore, we assessed
other RTK downstream effector pathways that could be
targets for PTPN12-mediated regulation driving tumor
growth. Phosphorylation of STAT3 has been implicated
in the growth of angiosarcoma cells [38] however neither
rapamycin nor trametinib treated tumors were found to
have consistently elevated levels of phospho-STAT3
Y705 (Supplementary Figure 6B, 6C). We also assessed
the phosphorylation of focal adhesion kinase (FAK), a
known target of PTPN12 [39] and found that recurring
tumors in trametinib treated mice did not have an increase
in FAK phosphorylation (Supplementary Figure 6C).
While other growth promoting pathways may be involved
in tumor regrowth in mice treated with a single agent, it is
possible that tumor proliferation is driven by a subtle shift
in signaling towards the mTOR pathway in tumors treated
with trametinib and towards the MAPK pathway in tumors
treated with rapamycin, emphasizing the importance
of simultaneous inhibition of both pathways in order to
achieve a sustained response.

www.oncotarget.com

Five snap frozen aliquots of angiosarcoma were
obtained from the pathology biobank at Cincinnati
Children’s Hospital Medical Center. Signaling in these
tumors was compared to tumors from all three mouse
genotypes as well as to HUVECs with and without
stimulation by VEGFA (Figure 5A). VEGFR2 was
expressed in the human angiosarcoma samples in three of
the tumors while VEGFR1 and PDGFR-β were detected
in four each. Both the mTOR and MAPK pathways
were activated as demonstrated by phospho-4EBP1 and
phospho-MAPK respectively (Figure 5A). Anti-phosphotyrosine western blotting demonstrated an overlapping
pattern of tyrosine phosphorylated proteins in the human
angiosarcoma samples compared to tumors from our
mouse models (Supplementary Figure 7).
A panel of human tumors of vascular origin were also
analyzed by IHC (Figure 5B). The endothelial origin of all of
the tumors was confirmed by showing immunoreactivity for
CD31. Interestingly, PTEN expression was largely absent in
high-grade tumors (angiosarcoma and lymphangiosarcoma)
while phosphorylation of S6 and MAPK was present in all
tumor types. Further, expression of the PTPN12 protein
was also very low in this panel of tumors when compared
to normal blood vessels. PDGFR-β was not detectable by
IHC in the angiosarcoma sample but was found in other
tumors of vascular origin. Collectively, these results suggest
that at least a subset of human angiosarcomas could benefit
from treatment that we find to be effective against our
murine angiosarcoma model. Furthermore, other tumors of
endothelial cell origin have similar pathway activation and
may also respond to this treatment regimen.

DISCUSSION
We developed a novel and robust genetically
engineered mouse model for angiosarcoma through the
combined deletion of Pten, Trp53, and Ptpn12. Conditional
deletion of all three genes results in aggressive cutaneous
tumors in mice that develop rapidly and with virtually
100% penetrance. The vascular origin of these tumors was
confirmed by immunohistochemical staining of tumors
for vascular markers, confirmation of rare endothelial
cells in the skin targeted by the GFAP-CreER driver line
and recapitulation of the angiosarcoma phenotype using
a more specific vascular endothelial driver, Tie2-CreER.
Notably, the vascular tumors from our models did not
express PROX1 and did not have associated lymphatic
effusions, indicating that these tumors were most
likely angiosarcomas rather than lymphangiosarcomas.
Recently, investigators used a different endothelial mouse
driver line to conditionally ablate Tsc1 and to activate
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model, conditional deletion of Pten alone did not result
in any tumors [41]. Finally, unlike the previous report,
we have combined activation of mTORC1 signaling with
other oncogenic drivers specific to angiosarcomagenesis.
This combination, and in particular inactivation of Ptpn12,
was highly associated with the angiosarcoma phenotype in
mice. The comparative study of these two valuable animal
models may elucidate critical differences in the biology
and cell of origin for these two related vascular tumors.
They may also help to define the appropriate molecular
targets for therapeutic intervention of these two entities,
which are currently treated with approaches resulting in
overall poor outcomes.

mTORC1 signaling in the vascular endothelium [40].
These mice primarily develop cutaneous and hepatic
lymphangiosarcoma. Moreover establishment of an
autocrine VEGF signaling loop was shown to contribute
to tumor growth in this model. The differences in tumor
phenotype between the current report and the study of Sun
et al. are likely multifactorial. First, different populations
of endothelial cells and/or progenitors are targeted by the
different mouse driver lines used. Second, while mTORC1
signaling in endothelial cells was induced in both studies,
this was accomplished by inactivating different nodes of
the pathway which is likely to result in a different pattern
of secondary signals. It is interesting to note that in our

Figure 4: Long-Term Treatment using both rapamycin and trametinib results in sustained disease regression.

(A) Comparison of change in tumor volume in long-term treatments of tumor-bearing TKO mice. The red arrow represents when mice
were taken off treatment at 140 days. Black arrows with lower-case letters represent the time points at which samples were analyzed in
(D). The table below indicates the number of mice remaining from each cohort at the indicated time points. (B) Disease-related mortality
analyzed by Kaplan–Meier. Non-tumor related deaths are indicated by the black tick marks. Statistical significance beside each curve is
compared with the dual drug treatment. **P ≤ 0.01, ****P ≤ 0.0001. (C) Waterfall plot showing the best responses in drug-treated tumors
and maximum growth in vehicle-treated tumors. (D) Immunohistochemistry comparing mTOR and MAPK signaling, proliferation and
apoptosis at various timepoints. Letters in the lefthand panels correspond to the timepoints when tissue was harvested as delineated in (A).
Scale bar in vehicle cleaved caspase-3 panel represents 50 µm and applies to all panels. (E) Quantification of TUNEL staining shown in
(D). (F) Quantification of KI67 staining shown in (D).
www.oncotarget.com
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Table 1: Comparison of best responses to rapamycin, trametinb or combined treatment
Response to Treatment
PR (50% Decrease)
<PR
Comparison
Dual
Rapamycin
Trametinib
Vehicle

14
6
5
0

1
6
7
6

Dual vs Veh
Dual vs Rapa
Dual vs Tram
Rapa vs Veh
Rapa vs Tram
Tram vs Veh
Abbreviations: PR – partial response; Veh – vehicle; Rapa – rapamycin; Tram 013; trametinib.
As previously mentioned, one striking finding of
this study was the association of Ptpn12 recombination
and inactivation in endothelial cells with the development
of angiosarcoma. Vascular tumors were not observed in
other targeted combinations of tumor suppressor deletion
using the same Cre driver line [41] including substitution
of Ptpn12 deletion in this model by activation of MAPK
signaling through the expression of a BRAF mutant
allele (BRAF V600E; ARS and LMLC, unpublished
data). These results suggest that the PTPN12 protein
is a tumor suppressor for endothelial cells and that it
regulates pathways that govern malignant progression to
angiosarcoma. We analyzed the activation status of known
PTPN12 substrates and RTKs expressed in vascular
endothelial cells and several were found to be tyrosine
phosphorylated in angiosarcoma. However PDGFR-β
was the only substrate whose phosphorylation was reliably
elevated when compared to control tissue and it was the
only RTK that was phosphorylated in angiosarcomas
from all three genetic crosses. While PDGFR-β is
predominantly a marker of pericytes [42], there are several
reports suggesting that its expression can be induced in
endothelial progenitor cells particularly in the context
of proliferation in response to vascular injury [43, 44].
Additional studies will focus on elucidating other critical
substrates of PTPN12 loss in angiosarcoma which could
lead to the identification of novel targets for therapy.
PTPN12 is a candidate tumor suppressor gene
in several human cancers including breast cancer,
hepatocellular carcinoma, oral squamous cell carcinoma,
colon cancer, esophageal cancer, non small cell lung
cancer, nasopharyngeal carcinoma, and glioblastoma
[24, 31, 33, 35, 45–49], however it has not been studied
in the context of human angiosarcoma. Recently another
PTP, PTPRB, was found to be mutated in 26% of
angiosarcomas [16]. PTPRB, which is also referred to
as VE-PTP, has been shown to dephosphorylate and to
regulate the activity of TIE2 and VEGFR2 in endothelial
cells [50, 51]. TIE2 appears to be an especially sensitive
substrate in mature endothelium as targeted inhibition of
PTPRB was demonstrated to activate receptor signaling
and to reduce neovascularization associated with macular
www.oncotarget.com

p-value
0.0002
0.054
0.009
0.043
0.685
0.1141

degeneration and diabetic retinopathy [52]. However,
the substrates of PTPRB in endothelial progenitor cells
have not been elucidated nor have they been studied in
the context of angiosarcoma. Our results suggest that
PTPN12 may phenocopy the tumor suppressor role of
PTPRB in murine endothelial cells. Alternatively, PTPRB
may be one of several PTPs involved in the pathogenesis
of endothelial cell-derived tumors. It should be noted that
potentially inactivating mutations of other PTP-encoding
genes were found with low frequency in whole exome/
genome sequencing of tumor DNA [16, 17]. While
PTPN12 was not one of these genes, the number of
angiosarcoma genomes that have been sequenced to date
remains small.
The contribution of RTK signaling to the
pathogenesis of angiosarcoma was suggested with the
finding of amplifications and mutations in the genes
encoding the VEGFR2 and VEGFR3 [53, 54]. The
description of PTPRB mutations in angiosarcoma not
only reconfirms the importance of RTK signaling in
this tumor, but also raises the possibility that a broader
range of RTKs expressed (or misexpressed) in endothelial
cells may be derepressed and contribute to oncogenesis.
We confirmed that PDGFR-β is phosphorylated in these
murine angiosarcomas, however activation of other
RTKs was also suggested by our screening RTK array
experiment (Supplementary Figure 2H). These findings
have important implications in the treatment of patients
with angiosarcoma. Contemporary clinical trials have
focused on targeting RTKs involved in angiogenesis
with monoclonal antibodies such as bevacizumab [55] or
targeted kinase inhibitors such as sorafenib and pazopanib
[56–58]. Overall, the clinical benefit of these treatments
has been short-lived with progression free survival (PFS)
ranging from 1.8 to 3.8 months in these studies. This is
comparable to the PFS of 4 months reported in a Phase II
trial of paclitaxel alone [59]. Furthermore, in a randomized
Phase II trial of paclitaxel compared to paclitaxel and
bevacizumab, no improvement in PFS was seen with the
addition of the antiangiogenic agent to chemotherapy
[60]. The lack of overall response in these clinical trials
may therefore be due to redundancy of RTKs expressed
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Figure 5: Murine angiosarcomas closely mimic human disease. (A) Western blot analysis of protein lysates prepared from
HUVECs treated (+) or untreated (–) with VEGFA, angiosarcomas from all three mouse genotypes, and a panel of human angiosarcomas.
(B) IHC analysis of normal human skin blood vasculature compared with the indicated endothelial cell tumor types. Scale bar in top right
panel is 50 µm and applies to all panels.
www.oncotarget.com
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and activated in angiosarcoma and/or direct mutational
activation of downstream effectors that are not dependent
on RTK activity. Our work suggests that a more robust and
durable response to therapy may be obtained by targeting
two primary downstream effector pathways of RTKs.
We investigated the activation status of the PI3K/
mTOR and MAPK pathways in murine angiosarcoma and
found both to be active in all three genetic combinations.
Moreover, in concordance with other studies, these
pathways were also found to be activated in human
angiosarcoma as well as other vascular tumors. Therefore
we investigated the effect of inhibition of these pathways
separately and in combination in vivo in our mouse
model using the FDA-approved drugs rapamycin, an
mTOR inhibitor and trametinib, a MEK inhibitor. First
we determined that administration of these drugs at doses
relevant to clinical applications effectively inhibited the
intended targets. We were surprised that five-day courses
of either drug resulted in significant regression of tumor
volume. However tumor resistance to monotherapy
was heralded by the observation of reciprocal pathway
hyperactivation. Indeed, long term monotherapy resulted
in inevitable tumor regrowth. We found that combined
therapy was not only able to prevent reciprocal pathway
hyperactivation but resulted in a more profound and
sustained tumor regression than either drug alone.
A significant limitation of our study is the mortality
of mice due to toxicity from the combined agents. To
mitigate these effects, we defined the minimally effective
biochemical dose of each agent independently, then
decreased each drug by one dose level in combination
(1 mg/kg each). We conducted a further in vivo dose deescalation study to 0.5 mg/kg of each drug in combination
which is 25% and 17% respectively of the minimally
effective biohemical dose of trametinib and rapamycin in
this model (data not shown). Remarkably, this combination
also resulted in sustained anti-tumor activity comparable
to higher doses, but still caused treatment limiting toxicity
in mice. Nevertheless, it should be noted that combinations
of MEK and mTOR inhibitors have been studied in early
phase clinical trials [61, 62]. Both trials were designed
to achieve doses as close to the recommended single
agent dose as possible. One trial was a Phase I dosefinding study of the combination of trametinib and the
rapalog, everolimus and was deemed to have failed due
to the inability of patients to tolerate pre-defined optimal
doses [62]. However, no pharmacodynamic analyses of
tumor tissue were conducted to look for target inhibition.
Importantly, no dose-limiting toxicities were reported at
the starting dose level which corresponded to 25% of the
single agent dose for trametinib and 50% for everolimus.
In the second trial, which was a Phase II trial of the MEK
inhibitor, selumetinib given at 67% if the single agent dose
and the rapalog, temsirolimus given at 100% (subsequently
reduced to 80%), less than 10% of patients who received
the combined treatment withdrew from the study due to
www.oncotarget.com

toxicity [61]. Again no pharmacodynamic studies in tumor
tissue were conducted in this trial. The dramatic response
to combined in vivo mTOR and MEK inhibition which
we have observed in our genetically engineered animal
model for angiosarcoma should renew efforts to design
clinical trials for patients with this disease. We suggest that
these trials should incorporate tumor pharmacodynamic
analyses in order to determine target inhibition, a dose
de-escalation scheme, and adequate supportive care to
mitigate the incidence of mucosal inflammation and
stomatitis which were the most frequent grade 3 toxicities
noted in previous clinical trials of combined therapy.

MATERIALS AND METHODS
Mice
Mice used in this study were backcrossed to the FVB/
NJ background for at least six generations unless otherwise
noted below. The GFAP-CreER, Trp53 floxed, Pten floxed
and Ptpn12 floxed mice have been previously reported
[63–66]. The Rosa-tdTomato reporter mouse (Jackson
Laboratory, Bar Harbor, ME, USA; stock no. 007909) was
backcrossed to FVB/NJ for three generations for these
experiments. The endothelial specific Tie2-CreERT2 mouse
will be described elsewhere (Y.F. and Y.Z., submitted) and
was maintained on the C57Bl6 background. Tamoxifen
(Sigma-Aldrich, St. Louis, MO, USA) was prepared and
administered to mice as previously described [41]. Mice were
observed daily and euthanized following NIH guidelines. All
mouse experiment were conducted after review and approval
from the Animal Care and Use Committee of Cincinnati
Children’s Hospital Medical Center. Tissue collection and
preparation has been previously described [41].

Drug treatments
For rapamycin (LC Laboratories, Woburn, MA,
USA) 25 mg/kg dosing, a stock solution of 50 mg/ml in
dimethyl sulfoxide (DMSO; Sigma-Aldrich) was made.
Prior to treatment this solution was diluted to a working
solution of 2.5 mg/ml in 5.2% Tween 80 (Sigma-Aldrich)
in ddH2O. For all other doses, a stock solution of 10 mg/ml
was used and diluted to working solutions of 1, 0.5, 0.3, and
0.1 mg/ml. For trametinib (LC Laboratories) dosing,
a stock solution of 10 mg/ml in DMSO was made and
diluted to working solutions of 0.3, 0.2, and 0.1 mg/ml
in 5.2% Tween 80 prior to use. All stock solutions were
aliquoted and stored at –20° C for up to one week.
Working solutions were prepared daily and mice were
treated with 100 µl/10 g body weight to achieve the
desired dose. Rapamycin was administered through
intraperitoneal injection while trametinib was given via
oral gavage. Vehicle solutions (DMSO with no drug) were
prepared and administered in the same manner as the drug
treatments. Mice treated with rapamycin were euthanized
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2 hours after the last dose, trametinib treated mice 4 hours
after the last dose, and dual treated mice 3 hours after the
last dose. Tumors were measured by calipers three times
weekly and mice were weighed once weekly throughout
treatment.

citrate buffer and microwave heating. The antibodies
used in IHC were anti-CD31 (1:100), anti-PROX1 (gift
from M. Nakafuku, CCHMC; 1:2000), anti-KI67 (Leica
Microsystems, Bannockburn, IL, USA; NCL-Ki67p,
1:4000), anti-PTEN (1:1000); anti-pS6 (1:5000), antipMAPK (1:400), anti-PDGFR-β (1:200), anti-cleaved
caspase-3 (BD Biosciences; 559565, 1:500) and antiPTPN12 (1:1000). The appropriate biotinylated secondary
antibodies (1:200) were used in conjunction with
horseradish peroxidase-conjugated streptavidin (Elite
ABC; Vector Labs, Burlingame,CA, USA), revealed with
DAB or VIP substrate (Vector Labs) and counterstained
with hematoxylin or methyl green respectively (Vector
Labs). The antibodies used in IF were anti-β-galactosidase
(Aves Labs, Tigard, OR, USA; BGL-1040, 1:1000) and
anti-CD31 (1:100). β-galactosidase staining was revealed
with a donkey anti-chicken antibody conjugated to
Alexa 488 (Jackson ImmunoResearch, West Grove, PA,
USA; 1:200). CD-31 was detected using the Tyramide
Amplification method [67]. Briefly, after incubation
with the primary antibody, slides were incubated with
biotinylated goat anti-rat secondary antibody, followed
by Elite ABC (Vector Labs). This was followed by
reaction with biotinylated tyramide and revealed with
streptavidin conjugated to Cy3 or Alexa 488 (Jackson
ImmunoResearch; 1:200). Terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) assay was
performed with the ApopTag Kit (Millipore) according to
the manufacturer’s instructions.

Endothelial cell isolation
Sheep anti-Rat magnetic Dynabeads (Thermo Fisher
Scientific, Waltham, MA, USA), 200 µl/sample, were
couple to 5 µl of anti-CD31 antibody (BD Biosciences,
Franklin Lakes, NJ, USA; 553370) according to the
manufacturer’s instructions. Cells were obtained from the
lungs of adult (>8 week old) FVB mice. The lungs were
dissected, minced, and incubated in DMEM media with
Collagenase Type 1 (Thermo Fisher Scientific) at 2 mg/
ml for 1 hour at 37° C. The tissue was passed through
a 70 micron filter (Greiner Bio-One, Monroe, NC, USA)
and centrifuged for 5 min. at 200g. The cell pellet was
resuspended in 2 ml phosphate buffered saline (PBS) +
0.1% bovine serum albumin (BSA) and added to the antiCD31 antibody-conjugated Dynabeads. The cells were
incubated on a rotator for 15 min. at room temperature
then washed three times in PBS + 0.1% BSA and the
resulting Dynabead attached cells used for protein lysate
preparation.

Western blot
Protein lysates from frozen tissues were prepared
and Western Blots performed as previously described
[41] using 10 to 25 µg total protein depending on the blot.
Antibodies used include the following from Cell Signaling
Technologies (Danvers, MA, USA; all of them used at
1:1000): anti-pAKT S473 (9271), anti-AKT (4685), antip4EBP1 (9459), anti-4EBP1 (9452), anti-pMAPK (9101),
anti-MAPK (9102), anti-PTEN (9559), anti-FAK (3285),
anti-VEGFR2 (2479) and anti-PDGFR-β (3169). Other
antibodies were also used at 1:1000 except where indicated:
anti-PTPN12 (Abcam, Cambridge, MA, USA; ab76492),
anti-VEGFR1 (Abcam; ab32152), anti-VEGFR3 (Thermo
Fisher Scientific; PA5-16871), anti-CD31 (Abcam;
ab28364), anti-actin (Sigma-Aldrich; A5441, 1:10000),
anti-VE-cadherin (Santa Cruz, Dallas, TX, USA; sc6458), anti-pTyr 4G10 (Millipore, Billerica, MA, USA;
05-321), anti-pFAK (Sigma; F7926). Blots were imaged
on a BioSpectrum Imaging System (UVP, Upland, CA,
USA) and quantification of bands was performed using the
instrument software.

Immunoprecipitation
Immunoprecipitation (IP) experiments were
performed using Dynabeads Protein A (Thermo Fisher
Scientific) conjugated to the indicated antibodies according
to the manufacturer’s instructions. For IP of tyrosinephosphorylated proteins the P-Tyr-1000 antibody was used
(Cell Signaling Technologies; 8954). IP was performed
using 500 µg of protein from CD31+ lung endothelial cells,
whole lung, and tumor lysates. Recovered proteins were
then run on Western Blots as described above and probed
for the indicated proteins.

RTK array
RTK array experiments were performed according
to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN, USA; ARY014) using 500 µg of protein
lysate on each array.

Immunohistochemistry/immunofluorescence

Polymerase chain reactions

Immunohistochemistry (IHC) and immunofluore
scence (IF) were performed as previously described
[41, 64]. IHC staining was performed on 5 µm thin
paraffin sections while IF staining was done on 12 µm
frozen sections. Antigen retrieval was performed using

Recombination of floxed alleles was detected by
polymerase chain reaction (PCR) using the following
oligonucleotides: for the Ptpn12 gene 5ʹ GCTCCAAG
GTTAAATGCCC 3ʹ and 5ʹ TCTATGCTGTGTAACTAGC
3ʹ; for the Pten gene 5ʹ TAGTTGGAGTCACCAGGATG
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3ʹ and 5ʹ AAGAGTCAAACAATGGCAAGC 3ʹ; and for
the Trp53 gene 5ʹ CACAAAAACAGGTTAAACCCAG
3ʹ and 5ʹ GAAGACAGAAAAGGGGAGGG 3ʹ. Expected
band sizes for the recombined products were 290 bp,
900 bp and 600 bp respectively.

AG), Cancer-Free Kids (LMLC), Sarcoma Foundation of
America (LMLC), and the Canadian Institutes of Health
Research (MOP-133679, AV). LMLC is a St. Baldrick’s
Foundation Scholar and a Distinguished Scientist of the
Sontag Foundation. We thank Masato Nakafuku and Tak
Mak for the gift of reagents and Ayesha Khan and Jillian
Goines for technical help.

Statistics
Statistical analysis was performed using GraphPad
Prism software. Quantitation of Western blots and 5-day
treatment tumor volumes utilized two-tailed Student’s
t test. Fisher’s Exact Test was used to compare response
rate of different treatment groups following long-term
treatment. Survival analyses were performed using the
method of Kaplan and Meier. Unless otherwise indicated,
statistical significance was as follows: *P ≤ 0.05,
**
P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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